GWM
ADAP

Geneos Wealth Management’s Adaptimmune Therapeutics ADAP Stock Holding History

Geneos Wealth Management’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-3,260
Closed -$18K – 2844
2021
Q1 		$18K Sell
3,260
-1,200
-27% -$6.87K ﹤0.01% 2117
2020
Q4 		$22K Buy
+4,460
New +$24.2K ﹤0.01% 1839

Other funds holding ADAP

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geneos Wealth Management's ADAP Position: Q2 2021 in Review

Geneos Wealth Management sold out of Adaptimmune Therapeutics (ADAP) in Q2 2021, closing a stake of 3,260 shares — an estimated $18K sold.

Geneos Wealth Management first reported a position in ADAP in Q4 2020 and held it in 2 quarters. The position peaked at $22K in Q4 2020. 82 funds tracked by Wall St. Rank hold ADAP as of Q2 2021.

  • Geneos Wealth Management reported no remaining Adaptimmune Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Geneos Wealth Management sold 3,260 Adaptimmune Therapeutics shares in Q2 2021, an estimated $18K.
  • Geneos Wealth Management first reported a position in Adaptimmune Therapeutics in Q4 2020 and held it in 2 quarters.
  • Geneos Wealth Management's Adaptimmune Therapeutics position peaked at $22K in Q4 2020.
  • 82 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q2 2021.

Based on Geneos Wealth Management's 13F filing for Q2 2021, filed 8 Jul 2021.